Stock VM VOYAGEUR PHARMACEUTICALS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Voyageur Pharmaceuticals Ltd. Toronto S.E.

Equities

VM

CA92916K1057

Pharmaceuticals

Delayed Toronto S.E.
Other stock markets
 		5-day change 1st Jan Change
- CAD -.--% Intraday chart for Voyageur Pharmaceuticals Ltd. +7.14% -.--%
04-26 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 29, 2024 CI
03-26 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2023 CI

Valuation

Fiscal Period: November 2018 2019 2020 2021 2022 2023
Capitalization 1 4.588 4.917 2.855 9.164 8.025 5.308
Enterprise Value (EV) 1 4.621 4.98 3.197 8.387 8.013 5.343
P/E ratio -7.27 x -7.81 x -2.48 x -4.15 x -4.3 x -3.73 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - -9,388,412 x -3,246,873 x -4,253,009 x -5,021,081 x -4,375,693 x
EV / FCF -9.01 x -8.35 x -58.1 x -7.96 x -6.73 x -9.15 x
FCF Yield -11.1% -12% -1.72% -12.6% -14.8% -10.9%
Price to Book 8.9 x 6.52 x 9.32 x 4.81 x 5.52 x 3.7 x
Nbr of stocks (in thousands) 53,975 65,563 71,366 101,820 114,638 132,702
Reference price 2 0.0850 0.0750 0.0400 0.0900 0.0700 0.0400
Announcement Date 4/5/19 4/3/20 3/30/21 3/17/22 3/30/23 3/26/24
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: November 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA - -0.5305 -0.9846 -1.972 -1.596 -1.221
EBIT 1 -0.8458 -0.5326 -1.138 -1.974 -1.605 -1.223
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -0.5559 -0.5523 -1.139 -2.051 -1.754 -1.399
Net income 1 -0.5559 -0.5523 -1.139 -2.051 -1.754 -1.399
Net margin - - - - - -
EPS 2 -0.0117 -0.009598 -0.0162 -0.0217 -0.0163 -0.0107
Free Cash Flow 1 -0.5126 -0.5962 -0.0551 -1.054 -1.19 -0.5838
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/5/19 4/3/20 3/30/21 3/17/22 3/30/23 3/26/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: November 2018 2019 2020 2021 2022 2023
Net Debt 1 0.03 0.06 0.34 - - 0.03
Net Cash position 1 - - - 0.78 0.01 -
Leverage (Debt/EBITDA) - -0.1188 x -0.3475 x - - -0.0282 x
Free Cash Flow 1 -0.51 -0.6 -0.06 -1.05 -1.19 -0.58
ROE (net income / shareholders' equity) -261% -87% -215% -185% -104% -96.5%
ROA (Net income/ Total Assets) -49.5% -23.2% -49.4% -64.2% -43% -35.9%
Assets 1 1.123 2.384 2.308 3.194 4.076 3.898
Book Value Per Share 2 0.0100 0.0100 0 0.0200 0.0100 0.0100
Cash Flow per Share 2 0 0 0 0.0100 0 0
Capex 1 0.33 0.18 0.16 0.43 0.28 0.17
Capex / Sales - - - - - -
Announcement Date 4/5/19 4/3/20 3/30/21 3/17/22 3/30/23 3/26/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 694B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 593B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 371B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 331B
ABBVIE INC. Stock AbbVie Inc.
+7.39% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 239B
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 209B
NOVARTIS AG Stock Novartis AG
+10.02% 209B
AMGEN INC. Stock Amgen Inc.
+8.49% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. VM Stock
  4. VM Stock
  5. Financials Voyageur Pharmaceuticals Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW